claritypharmaceuticals

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study. CLARIFY

Description:

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Contacts:

Clarity Pharmaceuticals

clinicaltrials@claritypharmaceuticals.com

+61 (0) 2 9209 4037

64Cu-SAR-bisPSMA

Isotope(s):
Target(s):
  • PSMA
Inclusion
  • • Untreated, histologically confirmed adenocarcinoma of the prostate
  • • High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.2023
  • • Patients electing to undergo RP with PLND.
Exclusion
  • •Patients with known predominant small cell or neuroendocrine PC
  • •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


United States 🇺🇸

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

Principal Investigator

Luke T. Nordquist, MD

View Profile

Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States

Principal Investigator

Neal Shore, MD

View Profile

Stanford University Medical Center

Stanford, California 94305, United States

Principal Investigator

Hong Song, MD, Ph.D.


Urology Clinics of North Texas

Dallas, Texas, United States

Principal Investigator

Alexander Parker, MD


Mayo Clinic - Phoenix

Phoenix, Arizona, United States

Principal Investigator

Jack Andrews, MD


Urology Associates of Nashville

Nashville, Tennessee, United States

Principal Investigator

David Morris, MD


Intermountain Health

Utah, United States

Principal Investigator

Dustin L. Boothe, MD


VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Principal Investigator

Gholam Berenji, MD


The Urology Place

San Antonio, Texas, United States

Principal Investigator

Naveen Kella, MD


Corewell Health

Michigan, United States

Principal Investigator

Brian R. Lane MD


BAMF Health

Grand Rapids, Michigan 49503, United States

Principal Investigator

Harshad Kulkarni, M.D.


Urologic Specialists

Tulsa, Oklahoma 74146, United States

Principal Investigator

Shaun GS Grewal, MD


University of Texas Southwestern Medical Center

Dallas, Texas 75390, United States

Principal Investigator

Orhan K. Oz, MD, PhD


NorthShore University Health System

Glenview, Illinois 60026, United States

Principal Investigator

Brian Helfand, MD


University of Wisconsin

Madison, Wisconsin 53792, United States

Principal Investigator

Steve Y Cho, MD


Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Principal Investigator

Ephraim Parent, MD, PhD


Mayo Clinic - Rochester

Rochester, Minnesota, United States

Principal Investigator

Jeffrey Karnes, MD


Indiana University School of Medicine

Indianapolis, Indiana, United States


Australia 🇦🇺

St. Vincent's Hospital

Sydney, New South Wales, Australia

Principal Investigator

Professor Louise Emmett, MBChB, FRACP, FAANMS, MD


Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Principal Investigator

Professor Ian Vela, MBBS, PhD


XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468